We assessed if acceptability of the dapivirine vaginal ring for HIV prevention differed among
the subgroup of women who reported engaging in transactional sex prior to enrollment in …

We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV
prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase …

MTN-025/HOPE was an open-label trial of the dapivirine vaginal ring conducted in four
African countries between 2016 and 2018. Women were first offered one ring monthly (at …

For women in the United States who remain sexually active beyond child-bearing years,
susceptibility to HIV infection remains, yet condom use is low. We assessed acceptability of …

Background Confounding introduced by individuals' sexual risk behavior is potentially a
significant source of bias in HIV-1 prevention intervention studies. To more completely …

Although vaginal microbicides for HIV prevention are designed to be female-initiated, male
partner influence has been identified as one of the most significant factors impacting …

Background Two phase 3 clinical trials showed that use of a monthly vaginal ring containing
25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by …

Background: The MTN-020/ASPIRE trial evaluated the safety and effectiveness of the
dapivirine vaginal ring for prevention of HIV-1 infection among African women. A nested …

Background Antiretroviral medications that are used as prophylaxis can prevent acquisition
of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among …

As demonstrated by the Phase III clinical trial, MTN-020/ASPIRE, the monthly dapivirine
vaginal ring is well tolerated and reduces the risk of HIV-1 as a woman-initiated prevention …